HomeCompareINZY vs PEP

INZY vs PEP: Dividend Comparison 2026

INZY yields 50.00% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INZY wins by $249.3K in total portfolio value
10 years
INZY
INZY
● Live price
50.00%
Share price
$4.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$394.0K
Annual income
$79,849.97
Full INZY calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — INZY vs PEP

📍 INZY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINZYPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INZY + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INZY pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INZY
Annual income on $10K today (after 15% tax)
$4,250.00/yr
After 10yr DRIP, annual income (after tax)
$67,872.47/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, INZY beats the other by $13,956.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INZY + PEP for your $10,000?

INZY: 50%PEP: 50%
100% PEP50/50100% INZY
Portfolio after 10yr
$269.3K
Annual income
$71,640.23/yr
Blended yield
26.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

INZY
Analyst Ratings
6
Buy
3
Hold
Consensus: Buy
Price Target
$12.00
+200.0% upside vs current
Range: $4.00 — $16.00
Altman Z
-6.5
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
28
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INZY buys
0
PEP buys
0
No recent congressional trades found for INZY or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINZYPEP
Forward yield50.00%3.66%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$394.0K$144.7K
Annual income after 10y$79,849.97$63,430.49
Total dividends collected$314.4K$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$12.00$172.43

Year-by-year: INZY vs PEP ($10,000, DRIP)

YearINZY PortfolioINZY Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$15,700$5,000.00$10,854$514.44+$4.8KINZY
2$24,135$7,336.45$11,982$758.21+$12.2KINZY
3$36,365$10,540.42$13,526$1,136.44+$22.8KINZY
4$53,753$14,842.48$15,727$1,741.93+$38.0KINZY
5$78,020$20,504.11$19,012$2,750.28+$59.0KINZY
6$111,295$27,813.68$24,173$4,514.44+$87.1KINZY
7$156,166$37,080.39$32,789$7,793.80+$123.4KINZY
8$215,724$48,626.29$48,258$14,354.51+$167.5KINZY
9$293,602$62,776.77$78,586$28,686.63+$215.0KINZY
10$394,004$79,849.97$144,688$63,430.49+$249.3KINZY

INZY vs PEP: Complete Analysis 2026

INZYStock

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Full INZY Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this INZY vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INZY vs SCHDINZY vs JEPIINZY vs OINZY vs KOINZY vs MAININZY vs MOINZY vs PMINZY vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.